25 completed, 10 active not recruiting, 9 terminated, 3 recruiting. 51 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 51 | Completed 25, Active not recruiting 10, Terminated 9, Recruiting 3, Unknown 3, Not yet recruiting 1 |
| Phase 2 | 3 | Unknown 2, Completed 1 |
Follow Sunitinib: new trials by email Literature Review of Sunitinib trials Research Report on Sunitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy IDRX-42, Sunitinib - Gastrointestinal Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 450 | 2025-12-03 | 2026-10-05 |
| A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI Vorolanib Tablets+Everolimus, Sunitinib - Renal Cell Carcinoma (RCC) | Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 116 | 2025-09-25 | 2025-09-10 |
| Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma Benmelstobart, Anlotinib, Sunitinib - Non-Clear Cell Renal Cell Carcinoma | Phase 3 | Active not recruiting | Sun Yat-sen University | 126 | 2025-06-01 | 2026-10-20 |
| Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) Stereotactic body radiotherapy (SBRT), axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib - Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic | Phase 3 | Recruiting | Sun Yat-sen University | 252 | 2024-09-18 | 2026-01-15 |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib Ripretinib, Sunitinib - GIST | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 54 | 2023-12-13 | 2025-12-17 |
| Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma XL092, Nivolumab, Sunitinib Malate - Non-Clear Cell Renal Cell Carcinoma | Phase 3 | Active not recruiting | Exelixis | 317 | 2023-01-01 | 2026-07-29 |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors CGT9486, Sunitinib, Midazolam - Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer | Phase 3 | Recruiting | Cogent Biosciences, Inc. | 482 | 2022-04-14 | 2026-06-16 |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy RYZ101, Everolimus, Sunitinib - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | RayzeBio, Inc. | 343 | 2022-03-24 | 2026-10-05 |
| Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC savolitinib, durvalumab, sunitinib - Papillary Renal Cell Carcinoma | Phase 3 | Active not recruiting | AstraZeneca | 148 | 2021-10-28 | 2026-10-21 |
| Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib Famitinib capsules, Sunitinib Capsules - Gastrointestinal Stromal Tumors | Phase 3 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 185 | 2020-09-12 | 2024-02-09 |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer TQB2450, Anlotinib, Sunitinib - Advanced Renal Cancer | Phase 3 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 528 | 2020-08-25 | 2024-10-15 |
| Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer Biological : Toripalimab Drug: Axitinib, sunitinib - Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 | Phase 3 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 421 | 2020-08-20 | 2025-11-28 |
| Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC) Sunitinib Malate, TAS 102 - Colorectal Cancer, Metastasis | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 60 | 2019-10-01 | 2020-11-13 |
| A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study Atezolizumab, Bevacizumab, Alectinib - Cancer | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1000 | 2019-02-28 | 2026-10-22 |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Ripretinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 453 | 2019-02-08 | 2026-10-16 |
| A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) bempegaldesleukin, sunitinib, nivolumab - Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 3 | Terminated | Nektar Therapeutics | 623 | 2018-12-18 | 2023-04-11 |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Sunitinib, Lomustine - Glioblastoma Multiforme, Glioblastoma, Adult | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 100 | 2018-08-31 | 2021-04-19 |
| Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) Pembrolizumab, Epacadostat, Sunitinib - Renal Cell Carcinoma (RCC) | Phase 3 | Completed | Incyte Corporation | 129 | 2017-12-07 | 2026-05-22 |
| Savolitinib vs. Sunitinib in MET-driven PRCC. Savolitinib, Sunitinib - Carcinoma, Carcinoma, Renal Cell | Phase 3 | Active not recruiting | AstraZeneca | 60 | 2017-07-25 | 2026-07-14 |
| A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Nivolumab, Cabozantinib, Sunitinib - Renal Cell Carcinoma | Phase 3 | Completed | Bristol-Myers Squibb | 701 | 2017-07-23 | 2026-08-24 |
Showing 20 of 51. Sign in to see all of them.
Carcinoma, Renal Cell (20) · Gastrointestinal Stromal Tumors (9) · Kidney Neoplasms (6) · Breast Neoplasms (4) · Neoplasm Metastasis (4) · Neoplasms (3) · Carcinoma (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Kidney Diseases (2) · Adenoma, Islet Cell (1) · Brain Neoplasms (1) · Carcinoid Tumor (1) · Carcinoma, Islet Cell (1)
Pfizer (14) · Novartis Pharmaceuticals (3) · Amsterdam UMC, location VUmc (2) · AstraZeneca (2) · Bristol-Myers Squibb (2) · Deciphera Pharmaceuticals, LLC (2) · Hoffmann-La Roche (2) · National Cancer Institute (NCI) (2) · Sun Yat-sen University (2) · AB Science (1) · Argos Therapeutics (1) · Assistance Publique - Hôpitaux de Paris (1) · CM Chungmu Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Cogent Biosciences, Inc. (1)
United States (34) · Italy (33) · Germany (30) · Spain (30) · France (29) · United Kingdom (28) · South Korea (26) · Australia (25) · Canada (25) · Poland (21) · Netherlands (20) · Brazil (18) · Czechia (17) · Taiwan (16) · Belgium (15)
Arnaud Mejean, MD PhD (1) · Axel Le Cesne, M.D., Ph.D (1) · Brian Rini, MD (1) · Christopher G Wood, MD, FACP (1) · Giuseppe Procopio, MD (1) · Henk Verheul, Prof. M.D. (1) · Jianming Xu, MD (1) · Mark A Socinski (1) · Mark Jones, MD (1)
PMID 37146227, PMID 26457466, PMID 32203306, PMID 33058158, PMID 33947608, PMID 37526095, PMID 17046465, PMID 17215529, PMID 20104222, PMID 20203173, PMID 21306237, PMID 21858552, PMID 23358972, PMID 23857972, PMID 23964934, PMID 24081937, PMID 24323035, PMID 24338498, PMID 24687826, PMID 25577718, PMID 25952317, PMID 26685869, PMID 26702763, PMID 26969090, PMID 27000445, PMID 27238653, PMID 27718781, PMID 27720136, PMID 27836885, PMID 27924459, PMID 28161554, PMID 28278333, PMID 28410911, PMID 28945839, PMID 28967554, PMID 29161241, PMID 29374054, PMID 29439857, PMID 29562145, PMID 29654533, PMID 29773662, PMID 29788981, PMID 29853320, PMID 29860937, PMID 30412222, PMID 30658932, PMID 30779529, PMID 30779531, PMID 31079938, PMID 31427204
2016 (3), 2014 (2), 2015 (2), 2017 (2), 2023 (2), 2008 (1), 2025 (1), U10CA021115 (1), U10CA031946 (1), U10CA180820 (1), U10CA180821 (1)